Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEV7
- Development stage
- Unknown
- Lead developer
- Pevion Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Vaginal
01
Overview
PEV7 is a first-in-class therapeutic virosomal vaccine developed for the treatment of recurrent vulvovaginal candidiasis (RVVC). Developed by Pevion Biotech, the vaccine utilizes a virosome-based delivery system to present antigens from *Candida albicans*, aiming to stimulate a protective immune response in pre-menopausal women. The vaccine was evaluated in Phase I clinical trials using both intramuscular (PEV7B) and intravaginal (PEV7C) administration routes. In 2011, CSL Limited entered into an agreement for the right of first refusal to commercialize the product in Australia and New Zealand.
- Other names
- Candida vaccinevirosomal anti-Candida vaccine
Beyond the preview
Go deeper on PEV7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEV7.